Risk estimation from somatic mutation assays

被引:17
作者
Heddle, JA
Swiger, RR
机构
[1] Department of Biology, York University, Toronto, Ont. M3J 1P3
来源
MUTATION RESEARCH-REVIEWS IN GENETIC TOXICOLOGY | 1996年 / 365卷 / 1-3期
基金
加拿大自然科学与工程研究理事会;
关键词
lacI; lacZ; Dlb-1; cancer; mutation spectrum;
D O I
10.1016/S0165-1110(96)90015-9
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The ability to quantify somatic mutations in vivo provides a new source of toxicological information that is relevant to the assessment of cancer risk. The major experimental factors that influence the mutant frequency are age, time after treatment, treatment protocol, and tissue analyzed. In untreated mice, the mutant frequency increases very rapidly with age from conception to birth, more slowly from birth to adulthood, and very slowly thereafter. All somatic tissues studied so far in adults have similar mutant frequencies, The time after treatment (expression time) is the most important experimental variable. The minimum time for expression varies from one tissue to another. To be valid, comparisons between tissues and treatments must be made after complete expression of the mutations. Unfortunately, the minimum expression time has not been characterized in most tissues. Since carcinogens are tissue specific, and many chemicals are distributed in the body in complex patterns, it is to be expected that there will be differences in the frequency of mutation induced in different tissues, As yet this has not been extensively studied. Since the mutations detected by the transgenic assays are neutral, the mutants should accumulate as the integral of the mutation rate. Hence chronic treatment protocols should be more effective than acute and subacute protocols whenever they permit substantially larger doses to be delivered. Such protocols are more relevant to human exposure and are preferable for dose extrapolations. The importance of transcription in determining mutation rates is not yet known, but it is noteworthy that the transgenes are not transcribed whereas the loci involved in carcinogenesis are. The mutation spectrum is important for quantitative risk estimation. Risk estimation must also take into account the spectrum of mutations that are involved in the carcinogenic process in the tissue and the spectrum of mutations that are detectable by the assay. New assays are being used to quantify mutations in vivo in order to understand the carcinogenic process, to search for the environmental factors involved in human cancer, and to evaluate the carcinogenic hazard qualitatively.
引用
收藏
页码:107 / 117
页数:11
相关论文
共 69 条
[11]   TEMPORAL AND MOLECULAR CHARACTERISTICS OF MUTATIONS INDUCED BY ETHYLNITROSOUREA IN GERM-CELLS ISOLATED FROM SEMINIFEROUS TUBULES AND IN SPERMATOZOA OF LACZ TRANSGENIC MICE [J].
DOUGLAS, GR ;
JIAO, JL ;
GINGERICH, JD ;
GOSSEN, JA ;
SOPER, LM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (16) :7485-7489
[12]   SEQUENCE SPECTRA OF SPONTANEOUS LACZ GENE-MUTATIONS IN TRANSGENIC MOUSE SOMATIC AND GERMLINE TISSUES [J].
DOUGLAS, GR ;
GINGERICH, JD ;
GOSSEN, JA ;
BARTLETT, SA .
MUTAGENESIS, 1994, 9 (05) :451-458
[13]   DETECTION OF COMPLETE AND PARTIAL CHROMOSOME GAINS AND LOSSES BY COMPARATIVE GENOMIC INSITU HYBRIDIZATION [J].
DUMANOIR, S ;
SPEICHER, MR ;
JOOS, S ;
SCHROCK, E ;
POPP, S ;
DOHNER, H ;
KOVACS, G ;
ROBERTNICOUD, M ;
LICHTER, P ;
CREMER, T .
HUMAN GENETICS, 1993, 90 (06) :590-610
[14]  
ESHLEMAN JR, 1995, ONCOGENE, V10, P33
[15]  
Felton J. S, 1990, HDB EXPT PHARM, V94, P471
[16]  
FESTING MFW, 1993, J EXP ANIM SCI, V35, P210
[17]   DETERMINATION OF HPRT MUTANT FREQUENCIES IN T-LYMPHOCYTES FROM A HEALTHY PEDIATRIC POPULATION - STATISTICAL COMPARISON BETWEEN NEWBORN, CHILDREN AND ADULT MUTANT FREQUENCIES, CLONING EFFICIENCY AND AGE [J].
FINETTE, BA ;
SULLIVAN, LM ;
ONEILL, JP ;
NICKLAS, JA ;
VACEK, PM ;
ALBERTINI, RJ .
MUTATION RESEARCH, 1994, 308 (02) :223-231
[18]   THE HUMAN MUTATOR GENE HOMOLOG MSH2 AND ITS ASSOCIATION WITH HEREDITARY NONPOLYPOSIS COLON-CANCER [J].
FISHEL, R ;
LESCOE, MK ;
RAO, MRS ;
COPELAND, NG ;
JENKINS, NA ;
GARBER, J ;
KANE, M ;
KOLODNER, R .
CELL, 1993, 75 (05) :1027-1038
[19]   LOW-FREQUENCY AND LATE OCCURRENCE OF P53 AND DCC ABERRATIONS IN COLORECTAL TUMORS [J].
FROGGATT, NJ ;
LEVESON, SH ;
GARMER, RC .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1995, 121 (01) :7-15
[20]   TRANSGENIC ANIMALS IN TOXICOLOGY [J].
GOLDSWORTHY, TL ;
RECIO, L ;
BROWN, K ;
DONEHOWER, LA ;
MIRSALIS, JC ;
TENNANT, RW ;
PURCHASE, IFH .
FUNDAMENTAL AND APPLIED TOXICOLOGY, 1994, 22 (01) :8-19